BEIJING, April 10 (Xinhua) — Scientists at Stanford University are actively exploring whether gene editing technology can be used to fight the epidemic, but so far they have solved only a small part of the mystery, the university’s Department of Bioengineering conducted an experiment using genetically manipulated Crispr technology to fight the new coronavirus.
We may now be entering an era of “new weapons” based on Crispr technology to fight deadly viruses such as influenza and coronaviruses. The researchers point out that PAC-MAN technology could be a rapidly implementing pan-coronavirus strategy to deal with emerging pandemic strains.
Stanley Qi Lab, which holds the core crispr technology that interferes with cancer cells and treats diseases, uses “PAC-MAN(Human Cell Preventive Antiviral Crispr Technology) to attack viral cells through a “guided Crispr torpedo” that destroys the genetic composition of the virus, penetrates human cells, and then uses cellular mechanisms for self-replication.
In this special experiment, the lab’s Crispr technology system was used to search for and destroy the new coronavirus and place it in a solution containing the virus’s inert synthesis fragments, which, like all Crispr technology systems, consisted of two parts: an enzyme and a “guideRNA”. RNA directs an enzyme called Cas-13d to attach to a specific point in the new coronavirus genome, followed by a series of cuts. Crispr can be thought of as a pair of scissors and then only removed from the new coronavirus.
The results showed that Crispr therapy, which targets new coronaviruses, could reduce the number of viruses in the solution by 90 percent, and the researchers believe that if the program is effectively implemented, the sterilization rate is sufficient to prevent human infection with the new coronavirus.
The above studies suggest that we may be entering an era of “new weapons” based on Crispr technology to fight deadly viruses such as influenza and coronaviruses, and that PAC-MAN technology may be a rapidly implementing pan-coronavirus strategy to deal with emerging pandemic strains.
Objectively speaking, the stanford team’s latest study is a blueprint, or proof of concept, without clinical actual drug treatment stodaways in animals or human sons, and there are some important unknowns in the program, including that they did not conduct PAC-MAN tests on actual patients with the new coronavirus. They haven’t developed a system for implanting human cells, and even if it works, there’s still a long way to go to finally achieve clinical testing, and frankly, there’s zero chance of it being tested in humans in the next 4-6 months. This is equivalent to if we try to reach the moon and return safely, we need to build a space rocket in advance and reach the escape speed.
“In the history of human development, every major scientific breakthrough has gone beyond the science and technology of the time, such as quarantine technology developed in the 13th century, medical innovation in the 17th century, and 18th century vaccination technology,” said Laurie Zolos, senior adviser on social ethics at the University of Chicago. Crispr is a new technology that has not yet been proven in human diseases, but it is logical that it should work. “
Crispr’s ability to edit genes will increasingly be used to treat diseases, initially only for genetic diseases, but in recent years it has been used to treat infectious diseases, including the new coronaviruses that are currently ravaging the world. The Crispr technology program for the true prevention or treatment of new coronaviruses is also being used in projects to treat influenza and other infectious viruses, and in 2018, the U.S. Department of Defense Advanced Research began a four-year “preparation program” to use genetic methods to generate new medical countermeasures for the treatment of human patients, based on the proposed program. Stanley Qi Labs is understood to be one of the research groups working on the Crispr program design, and in April 2019 they began working on a flu treatment based on Crispr technology, which researchers at the lab took note of when the new coronavirus outbreak broke out earlier this year and in late January shifted its focus to viruses that change people’s lifestyles.
There is a huge challenge in dealing with this particular virus, with 30,000 nucleotides, while Crispr technology guides RNA to only 22 nucleotide regions, requiring a large number of bioinformatics calculations and experiments in order to locate the best attack location.
The treatment itself is a double-gene attack that directly affects the target virus, the researchers said. The first effect is to reduce the concentration of the virus genome in human cells, and the second is to prevent viral proteins from being produced, thus preventing the virus from replicating itself and destroying the body’s defenses.
The biggest problem so far is that researchers did not actually use the new coronavirus in their trials because they could not obtain samples of the virus or have no government authorization. Stanley Qi Lab has created a synthetic, non-replicating virus with the gene expression characteristics of the new coronavirus to replace the real new coronavirus.
The Stanford team believes their findings are important even if they are not tested for a real new coronavirus, and the results suggest that we can intervene in certain areas of the virus, not just in the conceptual phase, but will eventually lead to a rapid development of a treatment regimen.
But other researchers say that in order to prove that humans can eliminate the new coronavirus, it will be necessary to test with real samples of the virus. Another problem is that there is no Crispr-based virus delivery system, and a persistent problem in Crispr’s medical program is how to apply medical treatment to the right cells, the lungs are the target of new coronaviruses, and the lungs are a particularly tricky battleground – drugs are relatively difficult to access, filled with mucus, which can interfere with targeted treatment.
While there are many potential treatment options, the researchers say, no way has been found to use PAC-MAN technology to cause RNA to the virus, and some may have found a way to solve the problem, and they may have an efficient way to deliver drugs.
Professor Angelo led a team of researchers at Georgia Tech university in partnership with several universities that they believecould be used as a sprayer therapy, a aerosol inhalation device that allows patients to breathe based on Crispr technology. Currently, they are testing the mouse for a sprayer/Crispr combination therapy.
Ultimately, the study notes that using Crispr as a “preventive strategy” for treating new coronaviruses means the treatment can keep uninfected people away from the virus, but Crispr is a newer medical technology, with only three U.S. Drug Administration (FDA)-approved Crispr human trials. Although the treatment has not been found to cause health damage to patients, researchers are cautious that early trials that introduced genetically modified cells into the human body have led to malignant inflammation and, in some cases, even death. This is one of the pressing issues that your immune system does not accept, it may be a treatment to better balance risk and reward.
Ultimately, as with any new treatment, Crispr prophylaxis for viral infections still needs to be tested on animals and human bodies before going through the FDA’s rigorous vetting process.
Still, the paper may one day be seen as a milestone, and the ultimate hope of crispr-based technology systems is that once a new virus gene is identified, changing the previous treatment is a simpler process, and it can be achieved quickly, perhaps in the future our system will have no idea what kind of virus to deal with, all you have to do is change a simple part, and then be able to truly resist the new virus, but the CURRENT FDA approval of any new uses of the treatment. The new study suggests that perhaps the next pandemic will come, we will have more weapons to deal with than the current vaccine and drugs.